Please login to the form below

Not currently logged in
Email:
Password:

J&J extends its JLABS incubator scheme to Europe

The Belgian site will accommodate up to 30 life science start-ups

J&J

Johnson & Johnson has been talking up the benefits of its JLABS incubator strategy for R&D collaboration for some time, and is now setting up a unit in Belgium to debut the approach in Europe.

A year ago the company revealed it had signed more than 230 partnerships with life science companies as a result of JLABS, with more than 200 companies operating at its then eight sites east and west coasts of US and Canada. In the last year it has seen the number of hosted companies swell to more than 330 and these have raised a whopping $9.4bn in capital.

Now J&J has a European JLABS site in Beerse - its tenth after it opened its Shanghai site towards the end of last year - that it says will accommodate up to 30 life science start-ups “focused on innovations across the entire healthcare spectrum, including biotech, pharmaceuticals, medical devices, consumer and health tech sectors”.

It’s not a high stretch for the pharma company, as the Beerse location was already a J&J incubator called JLINX having been set up in 2016 as a partnership with Bioqube Ventures, and is located on the R&D campus where J&J’s pharma division Janssen was set up more than 60 years ago.

The switch to JLABS status is significant, however the Beerse site will operate under the same “no strings attached” premise as the other nine locations - in other words providing “infrastructure, expertise and funding opportunities” but leaving the incubator companies free to partner as they choose.

While most pharma companies have schemes to tap into early-stage companies through incubators and venture capital funds, the scale of J&J’s approach to what is sometimes called ‘open innovation’ is considered to elevate it above by its peers in the industry.

The 10 JLABS operate alongside four innovation centres centred around academic R&D hotspots in the US, UK and China as part of a global network trying to develop close ties with groups working on new therapies at early stages. J&J then has the opportunity to identify and nurture promising projects and - hopefully - be at the front of the queue for licensing and acquisition.

“Our goal is to attract the best and brightest talent in science and technology,” commented Bill Hait, J&J’s head of global external innovation. The JLABS project enables us to “work with partners in healthcare to help start new, highly innovative companies, providing a wealth of incubation options for our partners and insights to new innovation for our businesses around the globe”, he added.

Historically J&J has sourced around half its R&D projects externally, but has steadily been pushing that proportion higher since launching its open innovation drive a few years ago.

Article by
Phil Taylor

9th February 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics